SKITUDE
The merger of Skitude, the largest network of skiing apps, and the Skioo innovative skipass technology, which provides access to ski resorts with a single card and no waiting in line, aims to optimise sales channels for the more than 150 partnering ski resorts for the upcoming season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190604005775/en/
Alongside may other advantages, the strategy will consist of using post-payment systems to facilitate the user’s skiing experience, streamlining their access to the slopes, and helping the ski resorts position their products on their online platform.
“We are working so that skiers can purchase a ski pass ahead of time and load the ticket on their RFID card, or validate beforehand using a credit card, easily from their mobile on”, explained Skitude CEO Marc Bigas. “These principles of convenience and post-payment are already well-known thanks to popular services like Uber”, he added.
As a result, Skitude Chairman Yngve Tvedt explains, the combined digital platform will add a new dimension to the ski industry with a digital journey that is simpler and fun.
Thus, Tvedt assures, Skitude is participating in the “digitalisation of the sector” and agrees with Marc Bigas that this experience will offer “more convenience to the skier” as well as “powerful solutions for the mobile sales channels and marketing services” that will help ski resorts stay better connected with the needs of their current and potential customers.
New challenges
The merger of the two companies is also aimed at finding a way to push back against the stagnation of users in the industry, one of the sector's main challenges. “We are setting off on a journey to meet challenges using technology”, the company’s CEO stated, adding that the experience built up by both Skitude and Skioo over the years will become “valuable information for ski resorts”.
It is worth noting that the Girona-based company has always been committed to interacting with users “before, during and after their visit”, which, according to Bigas, “strengthens the competitiveness of the industry and enables it to continue moving forward”.
A community of more than 1.3 million skiers
The Skitude community is currently made up of more than 1.3 million skiers who have used the free applications that are compatible with the Skitude platform, most of them being the official applications of ski resorts.
It is a very active community. Thanks to the GPS Tracker that can log their runs, users have already logged activity at more than 1,200 ski resorts in 45 countries worldwide, and have been able to participate in more than 250 Challenges allowing them to win ski days, equipment like skis, boots or action cameras, and exclusive discounts.
The operation will allow consolidating the international project of 50 people, with offices in Girona, Lausanne and Oslo, and to continue researching to find dynamic solutions and improve the customer experience at ski resorts.
The shareholders of the company are comprised of the entrepreneurial partners Marc Bigas and David Huerva, Spanish investment funds, as well as the three Norwegian funds that own Skioo: Investinor, Canica and Norselab. Norselab counts the Olympic alpine ski champion Aksel Lund Svindal as an investor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005775/en/
Contact:
For more information: Àric Monterde +34-972-001-021 aric.monterde@skitude.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release
Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e
Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release
Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release
Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa
Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release
News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom